Most cited papers from Klinikum Leverkusen

Klinikum Leverkusen

What are the most cited papers from Klinikum Leverkusen?

The most cited paper from Klinikum Leverkusen is "FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial" (Volker Heinemann et al., 2014), with 1,759 citations. Next come "Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial" (1,515) and "Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer" (995).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 122 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Volker Heinemann et al. · The Lancet Oncology	31 Jul 2014	1,759
2	Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet	19 Feb 2013	1,515
3	Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Philippe Rougier, Eric Van Cutsem, Emilio Bajetta et al. · The Lancet	Oct 1998	995
4	Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial Douglas Wardlaw, Steven Ron Cummings, Jan Van Meirhaeghe et al. · The Lancet	25 Feb 2009	843
5	Natalizumab for Active Crohn's Disease Subrata K. Ghosh, Eran Goldin, Fiona H. Gordon et al. · New England Journal of Medicine	2003	814
6	COSMO-RS: An Alternative to Simulation for Calculating Thermodynamic Properties of Liquid Mixtures Andreas Klamt, Frank Eckert, Wolfgang Arlt · Annual Review of Chemical and Biomolecular Engineering Review	11 Jun 2010	621
7	Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia Klaus Hans Metzeler et al. · Blood	11 Jun 2016	542
8	Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial James R. Berenson, Robert Pflugmacher, Peter F. Jarzem et al. · The Lancet Oncology	17 Feb 2011	526
9	Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial Wolfgang Göpel, Angela Kribs, Andreas Ziegler et al. · The Lancet	30 Sep 2011	475
10	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial Christoph Röllig et al. · The Lancet Oncology Open access	5 Nov 2015	404
11	Crohn's Disease and Escherichia coli Helmut A. Malchow · Journal of Clinical Gastroenterology	Dec 1997	402
12	The COSMO and COSMO‐RS solvation models Andreas Klamt · Wiley Interdisciplinary Reviews Computational Molecular Science	28 Sep 2017	387
13	Nonintubated Surfactant Application vs Conventional Therapy in Extremely Preterm Infants Angela Kribs, Claudia Roll, Wolfgang Göpel et al. · Archives of Pediatrics and Adolescent Medicine Open access	8 Jun 2015	374
14	Prospective evaluation of complications in outpatient GI endoscopy: A survey among German gastroenterologists Andreas Sieg, Ulrike Hachmoeller-Eisenbach, Thomas Eisenbach · Gastrointestinal Endoscopy	May 2001	335
15	Impact of Physical Activity on Glycemic Control and Prevalence of Cardiovascular Risk Factors in Adults With Type 1 Diabetes: A Cross-sectional Multicenter Study of 18,028 Patients Barbara Bohn, Antje Herbst, M. Pfeifer et al. · Diabetes Care	26 May 2015	322
16	Development of new auxiliary basis functions of the Karlsruhe segmented contracted basis sets including diffuse basis functions (def2-SVPD, def2-TZVPPD, and def2-QVPPD) for RI-MP2 and RI-CC calculations Arnim Hellweg, Dmitrij Rappoport · Physical Chemistry Chemical Physics	19 Nov 2014	316
17	Oral budesonide for prevention of postsurgical recurrence in Crohn's disease Goran Hellers, Antoine Cortot, Derek P. Jewell et al. · Gastroenterology Open access	Feb 1999	300
18	Diabetic Nephropathy in 27,805 Children, Adolescents, and Adults With Type 1 Diabetes Klemens Raile, Angela Galler, Sabine E. Hofer et al. · Diabetes Care	28 Sep 2007	282
19	Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial Steven Boonen, Jan Van Meirhaeghe, Leonard Bastian et al. · Journal of Bone and Mineral Research Open access	17 Feb 2011	233
20	Diagnosis of Bacteremia in Whole-Blood Samples by Use of a Commercial Universal 16S rRNA Gene-Based PCR and Sequence Analysis Nele Wellinghausen, Anna-Julia Kochem, Claudia Disqué et al. · Journal of Clinical Microbiology Open access	2 Jul 2009	226
21	Safety assessment in development and operation of modular continuous-flow processes Norbert Kockmann, Philipp Thenée, Christoph Fleischer‐Trebes et al. · Reaction Chemistry & Engineering	2017	225
22	Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases Katja de With et al. · Infection Open access	11 Apr 2016	217
23	Patterns of multisite pain and associations with risk factors David Coggon et al. · Pain Open access	29 May 2013	197
24	Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial M.À. Gassull, Fernando Fernández‐Bañares, E. Cabré et al. · Gut Open access	28 Jul 2002	193
25	Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia Tobias Herold et al. · Leukemia Open access	30 Mar 2020	192
26	Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease Stefan Schreiber, Susanna Nikolaus, H Malchow et al. · Gastroenterology Open access	May 2001	189
27	Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis Pierre Dominique Delmas, Bernard Vrijens, Richard Eastell et al. · The Journal of Clinical Endocrinology & Metabolism	24 Jan 2007	186
28	Disabling musculoskeletal pain in working populations: Is it the job, the person, or the culture? David Coggon et al. · Pain Open access	18 May 2013	180
29	The CUPID (Cultural and Psychosocial Influences on Disability) Study: Methods of Data Collection and Characteristics of Study Sample David Coggon et al. · PLoS ONE Open access	6 Jul 2012	178
30	Indications for cardiovascular magnetic resonance in children with congenital and acquired heart disease: an expert consensus paper of the Imaging Working Group of the AEPC and the Cardiovascular Magnetic Resonance Section of the EACVI Emanuela R. Valsangiacomo Buechel et al. · European Heart Journal - Cardiovascular Imaging Open access	17 Feb 2015	176
31	CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome Franziska Taube et al. · Blood Open access	28 Jul 2021	174
32	Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial Claus‐C. Glüer et al. · Journal of Bone and Mineral Research Open access	15 Jan 2013	174
33	Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study Johann Diederich Ringe, Alfred Dorst, Herbert Faber et al. · Osteoporosis International	Oct 2003	173
34	Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study Johann Diederich Ringe, Herbert Faber, Parvis Farahmand et al. · Rheumatology International	6 Jul 2005	169
35	Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms Gerd Goeckenjan et al. · Pneumologie Open access	Mar 2010	166
36	Future Production Concepts in the Chemical Industry: Modular – Small‐Scale – Continuous Thomas Bieringer, Sigurd Buchholz, Norbert Kockmann · Chemical Engineering & Technology	13 May 2013	166
37	Infection Reduction Using Antibiotic-Coated Inflatable Penile Prosthesis Steven K. Wilson, Jürgen Zumbe, Gerard D. Henry et al. · Urology	Aug 2007	163
38	Impact of storage conditions and storage time on silver nanoparticles' physicochemical properties and implications for their biological effects Emilia Izak‐Nau, Anna Huk, Brian Reidy et al. · RSC Advances Open access	2015	162
39	Solubility prediction, solvate and cocrystal screening as tools for rational crystal engineering Christoph Loschen, Andreas Klamt · Journal of Pharmacy and Pharmacology Open access	8 Apr 2015	162
40	Inborn errors in RNA polymerase III underlie severe varicella zoster virus infections Benson Ogunjimi et al. · Journal of Clinical Investigation Open access	6 Aug 2017	160
41	Laparoscopic Radical Prostatectomy - the Experience of the German Laparoscopic Working Group Jens Jochen Rassweiler, Jens Uwe Stolzenburg, Tullio Sulser et al. · European Urology	3 Nov 2005	159
42	Origin, evolution, and global transmission of community-acquired Staphylococcus aureus ST8 Lena Strauß, Marc Stegger, Patrick Eberechi Akpaka et al. · Proceedings of the National Academy of Sciences Open access	20 Nov 2017	157
43	Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · Blood	20 Nov 2009	157
44	Developing the biofacility of the future based on continuous processing and single-use technology Stephan Klutz, Jørgen Barsett Magnus, Martin Lobedann et al. · Journal of Biotechnology	16 Jun 2015	156
45	Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial Mathias Rummel, Ulrich Kaiser, Christina Balser et al. · The Lancet Oncology	4 Dec 2015	155
46	Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis Axel U Dignass, Bernd Bokemeyer, Henning Ernst Adamek et al. · Clinical Gastroenterology and Hepatology Open access	17 Apr 2009	154
47	COSMOSPACE: Alternative to conventional activity‐coefficient models Andreas Klamt, Gerard J. P. Krooshof, Ross Taylor · AIChE Journal Open access	Oct 2002	151
48	A Randomized Trial of Balloon Kyphoplasty and Nonsurgical Management for Treating Acute Vertebral Compression Fractures Jan Van Meirhaeghe, Leonard Bastian, Steven Boonen et al. · Spine Open access	27 Feb 2013	151
49	Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer Gerd Goeckenjan et al. · Pneumologie Open access	14 Dec 2010	150
50	COSMO-RS: A novel view to physiological solvation and partition questions Andreas Klamt, Frank Eckert, Martin Hornig · Journal of Computer-Aided Molecular Design	Apr 2001	143

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.